Baker Ellis Asset Management’s Actinium Pharmaceuticals ATNM Stock Holding History

Baker Ellis Asset Management’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-333	Closed	-$2K	–	219
2019 Q3	$2K	Hold	333	–	–	﹤0.01%	236
2019 Q2	$2K	Hold	333	–	–	﹤0.01%	230
2019 Q1	$5K	Hold	333	–	–	﹤0.01%	214
2018 Q4	$4K	Hold	333	–	–	﹤0.01%	218
2018 Q3	$7K	Hold	333	–	–	﹤0.01%	240
2018 Q2	$6K	Hold	333	–	–	﹤0.01%	241
2018 Q1	$4K	Buy	+333	New	+$5.66K	﹤0.01%	236

Other funds holding ATNM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

CAN

Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return

Baker Ellis Asset Management's ATNM Position: Q4 2019 in Review

Baker Ellis Asset Management sold out of Actinium Pharmaceuticals (ATNM) in Q4 2019, closing a stake of 333 shares — an estimated $2K sold.

Baker Ellis Asset Management first reported a position in ATNM in Q1 2018 and held it in 7 quarters. The position peaked at $7K in Q3 2018. 45 funds tracked by Wall St. Rank hold ATNM as of Q4 2019.

Baker Ellis Asset Management reported no remaining Actinium Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Baker Ellis Asset Management sold 333 Actinium Pharmaceuticals shares in Q4 2019, an estimated $2K.
Baker Ellis Asset Management first reported a position in Actinium Pharmaceuticals in Q1 2018 and held it in 7 quarters.
Baker Ellis Asset Management's Actinium Pharmaceuticals position peaked at $7K in Q3 2018.
45 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q4 2019.

Based on Baker Ellis Asset Management's 13F filing for Q4 2019, filed 10 Feb 2020.